} ?>
(Yicai Global) Nov. 25 -- Japanese pharmaceutical giant Esai will use gene testing products independently developed by China's Amoy Diagnostics in China and Japan to seek ways to find cures to a rare form of cancer that develops in bile ducts.
Amoy and Esai penned a cooperation agreement regarding the use of the reagent for cholangiocarcinoma research, the Xiamen-based maker of kits to detect genetic mutation said in a statement on Nov. 22, without disclosing financial details.
Before this, Amoy's diagnostic technologies have been used by global firms such as Loxo Oncology, a unit of Eli Lilly, and US Pfizer to develop cancer drugs in Asia. The company has obtained approvals to sell its products in Japan and South Korea.
Amoy's [SHE: 300685] stock price rose by 0.6 percent to CNY71.90 (USD10.20) this morning. Its shares have nearly doubled in value this year.
Editor: Emmi Laine